The management of superficial transitional cell carcinoma of the bladder: A critical assessment of contemporary concepts and future perspectives

BJU International

Volumn 96, Issue 8, 2005, Pages 1171-1176

  Vögeli, Thomas Alexander ^a  

^a UNIVERSITY OF AACHEN MEDICAL CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CYTOSTATIC AGENT;

BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER SURGERY; CYSTECTOMY; DISEASE SEVERITY; DRUG INSTILLATION; FLUORESCENCE; HISTOPATHOLOGY; HUMAN; PRIORITY JOURNAL; REOPERATION; REVIEW; SURGICAL TECHNIQUE; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TUMOR BIOPSY;

CARCINOMA, TRANSITIONAL CELL; FLUORESCENCE; FORECASTING; HUMANS; NEOPLASM RECURRENCE, LOCAL; PHOTOSENSITIZING AGENTS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 28444455585     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05928.x     Document Type: Review

References (50)

1. Feldmann AR, Kessler L, Myers MH. The prevalence of cancer. N Engl J Med 1996; 315: 1394-7
2. Pyrah LN, Raper FP, Thomas GM. Report of a follow up of papillary tumours of the bladder. Br J Med 1964; 36: 14-25
3. Eble JN, Sauter G, Epstein JI, Sesterhenn IA eds. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. Lyon: IARC Press, 2004
4. Malmstrom PU, Busch C, Norlen BJ. Recurrence, progression and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow up. Scand J Urol Nephrol 1987; 21: 185-95
5. Cheng L, Neumann RM, Bostwick DG. Papillary urothelial neoplasms of low malignant potential. Clinical and biological implications. Cancer 1999; 86: 2102-8
6. Alsheik A, Mohamedali Z, Jones E, Materson J, Gilks CB. Comparison of the WHO ISUP classification and cytokeratin 20 expression in predicting the behavior of low grade papillary urothelial lesions. Mod Pathol 2001; 14: 267-72
7. Holmang S, Andius P, Hedelin H, Wester K, Busch C, Johannson SL. Stage progression in Ta papillary urothelial tumors. Relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 2001; 165: 1124-8
8. Meijeden A, Sylvester R, Colette L, Bono A, Ten Kate F. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 EORTC trials. J Urol 2000; 164: 1533-7
9. Pathologist of the French Association of Urology Cancer Committee. Lamina propria microinvasion of bladder tumors, incidence or stage allocation (pTa vs PpT1): recommended approach. World J Urol 1993; 11: 161-4
10. Witjes JA, Kiemeney LA, Schaffma HE, Debruyne FM. The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. Br J Urol 1994; 73: 172-6
11. Tosoni I, Wagner U, Sauter G, Egloff M, Nönagel H, Alund G. Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer. BJU Int 2000; 85: 48-53
12. Milner WA. Results in the treatment of bladder tumors. J Urol 1953; 69: 657-64
13. Bressel M, Kemper K. Vorbedingungen und Technik der transurethralen Resektion. Urologe A 1969; 8: 73-80
14. Marberger A, Marberger F, DeCristofero A. The current status of transurethral resection in the diagnosis and therapy of carcinoma of the urinary bladder. Int Urol Nephrol 1972; 4: 35-44
15. Flamm J, Steiner R. Stellenwert der differenzierten transurethralen Resektion beim primären oberflächlichen Harnblasenkarzinom. Urologe A 1991; 30: 111-3
16. Koloscy Z. Histopathological self control in transurethral resection of bladder tumours. Br J Urol 1976; 116: 575-80
17. Klän R, Loy V, Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol 1991; 46: 316-8
18. Köhrmann KU, Woeste M, Kappers JH, Rassweiler J, Alken P. Der Wert der transurethralen Nachresektion beim oberflächlichen Harnblasenkarzinom. Akt Urol 1994; 25: 208-13
19. Vögeli TA, Marx G, Ackermann R. Zur Notwendigkeit der Nachresektion beim oberflächlichen Blasenkarzinom als Kontrolle der Erstresktion. Urologe A 1991; 31: 59
20. Schwaibold HE, Treiber U, Kuebler H, Leyh H, Hartung R. Second transurethral resection detects histopathological changes worsening the prognosis in 25% of patients with T1 bladder cancer. J Urol 2000; 163: 153-4
21. Zurkirchen MA, Sulser T, Hauri D. Can a second resection be omitted in the treatment of bladder cancer. Eur Urol 2001; 39 (Suppl.): 119
22. Schips L, Augustin H, Zigeuner R, Trummer H, Pummer K, Hubmer G. Is a second transurethral resection justified in patients with newly diagnosed superficial bladder cancer. Eur Urol 2000; 37 (Suppl.): 111
23. Brausi M, Colette L, Kurth KH, van der Meijden AP, Osterlink W, Witjes JA. Variability in recurrence rate after first follow up cystoscopy after TUR in stage TaT1 transitional cell carcinoma of the bladder: a combined analysis of 7 EORTC studies. Eur Urol 2002; 41: 523-31
24. Brausi M, Sylvester R, van der Meijden A, Kurth KH. Does the surgeon have impact o the outcome of patients with TaT1 TCC of the bladder. Eur Urol 2001; 39 (Suppl.): 466
25. Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, Vögeli TA. Effect of routine transurethral resection for superficial bladder cancer: a long term observational study. J Urol 2003; 170: 433-7
26. Fitzpatrick JM, West AB, Butler MR, Lane V, O'Flynn JD. Superficial bladder tumors: the importance pattern following initial resection. J Urol 1986; 135: 920-4
27. Smith JA, Labasky RF, Ciockett ATK, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta,T1 and Tis). J Urol 1999; 162: 1697-701
28. MRC Working Party on Urological Cancer. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. Br J Urol 1985; 57: 680-3
29. Tolley DA, Hargreave TB, Smith PH, Williams JL, Parmar MK. Effect of intravesical mitomycin on recurrence of newly diagnosed superficial bladder cancer; interim report from the MRC Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br Med J 1988; 296: 1759-63
30. Oosterlinck W, Kurth KH, Schroeder FH, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta,T1 transitional cell bladder tumors: a prospective, randomized controlled study. J Urol 1993; 149: 749-52
31. Ali el Denein B, Nabeeh A, el-Baz M, Shamaa S, Ashamallah A. Single dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional cell bladder tumours: a prospective, randomized controlled study. Br J Urol 1997; 79: 731-4
32. Solsona E, Iborra I, Ricos J, Monros JL, Casanova J, Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long term follow up. J Urol 1999; 161: 1120-3
33. Rajala P, Liukkonen T, Raitanen M, Rintala E, Kaasinen E, Helle M. Transurethral resection with perioperative instillation on interferon alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study - FinnBladder III. J Urol 1999; 161: 1133-5
34. Rajala P, Kaasinen E, Raitanen M, Liukonen T, Rintala E and the FinnBladder Group. Perioperative single dose instillation of epirubicin or interferon alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study - FinnBladder III long term results. J Urol 2002; 168: 981-5
35. Okamura K, Ono Y, Kinukawa T, Matsuura O, Yamada S, Ando T. Randomized study of single early instillation of 1′R-4′-O-tetrahydropyranyl- doxorubicin for single superficial bladder carcinoma. Cancer 2002; 94: 2363-8
36. Sylvester RJ, Oosterlinck W, van der Meijden A. A single postoperative instillation of chemotherapy decrease the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta analysis of published results of randomized clinical trials. J Urol 2004; 171: 2186-90
37. Oosterlink W, Lobel B, Jakse G, Malmstrom PU, Stöckle M, Sternberg C. Guidelines on bladder cancer. Eur Urol 2002; 41: 105-12
38. Zaak D, Hungerhuber E, Reich O et al. Detection of bladder cancer with 5-ALA - results of 1713 fluorescence endoscopies. Eur Urol 2004; 43 (Suppl): 95
39. Daniltschenko D, Riedl C, Koenig F, Daha LK, Sachs M, Schnorr D. der Stellenwert der ALA (5-Aminolaevulinsäure) Fluoreszenzdetektion für die. Prognose des Oberflächlichen Blasenkarzinoms. Aktuel Urol 2004; 35: 497-501
40. Sachs MD, Daniltchenko D, Riedl CR et al. Fluorescence detection with 5-aminolevulinic acid reduces the risk of tumor recurrence and progression in patients with superficial bladder cancer: 5 year results of a prospective randomized trial. J Urol 2005; 173 (Suppl.): 921
41. Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M and the Hexvix PCB301/01 Study Group. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004; 171: 135-8
42. Vögeli TA, Ackermann R. When does superficial bladder cancer resist intravesical therapy? Semin Urol 1990; 8: 248-53
43. Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of superficial transitional cell carcinoma of the bladder: results of a meta analysis. Anticancer Res 2001; 21: 765-80
44. Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M. Intravesical bacillus Calmette Guerin versus mitomycin for TA and T1 bladder cancer. Cochrane Library 2003; Issue 3: Oxford: Update Software
45. Pawinski A, Sylvester R, Kurth KH et al. Combined analysis of European Organisation for Research and Treatment of Cancer and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. EORTC Cooperative Group and MRC Working Party on Superficial Bladder Cancer. J Urol 1996; 156: 1934-7
46. Kurth KH, Denis L, Bouffioux R et al. Factors affecting recurrence and progression in superficial bladder cancer. Eur J Cancer 1995; 31A: 1840-6
47. Millan-Rodriguez G, Chechile-Tomiolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000; 164: 680-4
48. Solsona E, Iborra I, Dumont J, Rubio-Briones J, Casanova J, Almenar S. The 3 month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 2000; 164: 685-9
49. Dugon F, Williamson P. Molecular markers for predicting recurrence and outcome of bladder cancer (Do the poster boys need more poster?). Curr Opin Urol 2004; 14: 277-849
50. Modlich O, Prisack B, Ramp U et al. Identifying superficial, muscle invasive and metastasising transitional cell carcinoma of the bladder: Use of cDNA array analysis of gene expression profiling. Clin Cnacer Res 2004; 10: 10-4